Side-by-side · Research reference

AdipotidevsAHK-Cu

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-MechanisticHUMAN-REVIEWED14/43 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

01Mechanism of Action

Parameter

Adipotide

AHK-Cu

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

AHK-Cu

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

Topical — scalp or dermal application

Frequency

Not specified in available data

Once or twice daily (topical application)

Evidence basis

Preclinical animal models only

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Human data

None — no clinical trials reported

—

Effective concentration (in vitro)

—

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

Topical formulation

—

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

Duration

—

Not established — cosmetic protocols typically 8–12 weeks

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

AHK-Cu

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

AHK-Cu

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Local irritation

—

Mild erythema, pruritus at application site (copper peptide class effect)

Copper sensitivity

—

Rare hypersensitivity reaction in copper-sensitive individuals

Systemic absorption

—

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

Data limitations

—

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

AHK-Cu

·Known copper allergy or Wilson's disease

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

05Administration Protocol

Parameter

Adipotide

AHK-Cu

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Once or twice daily. Evening application preferred for overnight contact time.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

5. Duration

—

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

06Stack Synergy

Adipotide

— no documented stacks

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support